A Multicenter, Randomized, Double-Blind, Parallel, 12-Week Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin Combination Tablet Versus Atorvastatin in Elderly Patients With Hypercholesterolemia at High or Moderately High Risk for Coronary Heart Disease

NCT00535405 Phase 3 COMPLETED Results posted

A multicenter study to evaluate the safety and efficacy of ezetimibe/simvastatin versus atorvastatin in elderly patients with high cholesterol at high or moderately high risk for coronary heart disease.

Details

Lead sponsor	Organon and Co
Phase	Phase 3
Status	COMPLETED
Enrolment	1289
Start date	2007-11
Completion	2009-03

Conditions

• Hypercholesterolemia

Interventions

• Atorvastatin 10 mg
• Ezetimibe 10 mg/simvastatin 20 mg
• Atorvastatin 20 mg
• Ezetimibe 10 mg/simvastatin 40 mg
• Atorvastatin 40 mg

Primary outcomes

• Percent Change From Baseline in Low Density Lipoprotein (LDL-C) at Week 12 — Baseline and 12 weeks